Targeted therapy of colorectal cancer - state of the art

The recent development of drugs that target the key components of biologic pathways rendered an improvement in survival in colorectal cancer patients. Two monoclonal antibodies in particular, targeting vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) - bevacizuma...

Full description

Saved in:
Bibliographic Details
Published inContemporary oncology (Poznań, Poland) Vol. 10; no. 3; p. 121
Main Author Utracka-Hutka, Beata
Format Journal Article
LanguageEnglish
Polish
Published Poznan Termedia Publishing House 15.03.2006
Subjects
Colorectal cancer
Online AccessGet full text

Cover

More Information
Summary:The recent development of drugs that target the key components of biologic pathways rendered an improvement in survival in colorectal cancer patients. Two monoclonal antibodies in particular, targeting vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) - bevacizumab and cetuximab are clinically available. The expectations with low molecular weight tyrosine kinase inhibitors in the treatment of colorectal cancer have not been confirmed. This review focuses on the defining role of the novel targeted agents in colorectal cancer.
ISSN:1428-2526
1897-4309